Health Care • Biotechnology: Pharmaceutical Preparations
$248.98 ▼ -2.29
(-0.91%)
MKT CAP: $16.55B • VOL: 480.0K
52W L $188 52W H $282
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$209
MEDIAN
$279
MEAN
$284
HIGH
$339
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ASND TAPE
ASND // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $301.27 | $286.33 | 2025-02-14 | $226.57 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $313.71 | $293.80 | 2025-02-06 | $234.04 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $283.84 | $273.88 | 2025-01-29 | $239.02 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $253.96 | — | 2025-01-17 | $244.00 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $219.10 | $236.53 | 2025-01-09 | $221.59 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $296.29 | $258.94 | 2024-12-18 | $216.61 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $241.51 | $251.47 | 2024-12-04 | $231.55 | -4.3% | 48% | C |